Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.91 Insider Own1.40% Shs Outstand51.75M Perf Week-5.24%
Market Cap740.03M Forward P/E- EPS next Y-2.88 Insider Trans-75.78% Shs Float46.75M Perf Month-14.88%
Income-133.80M PEG- EPS next Q-0.95 Inst Own- Short Float22.21% Perf Quarter-25.91%
Sales590.70M P/S1.25 EPS this Y-497.30% Inst Trans3.72% Short Ratio12.62 Perf Half Y-48.84%
Book/sh12.69 P/B1.13 EPS next Y39.90% ROA-12.80% Target Price20.78 Perf Year-44.14%
Cash/sh8.91 P/C1.61 EPS next 5Y29.00% ROE-27.80% 52W Range12.86 - 36.35 Perf YTD-8.22%
Dividend- P/FCF4.09 EPS past 5Y-26.10% ROI-22.30% 52W High-60.66% Beta1.54
Dividend %- Quick Ratio3.90 Sales past 5Y14.00% Gross Margin78.30% 52W Low11.20% ATR0.83
Employees484 Current Ratio4.00 Sales Q/Q1.20% Oper. Margin-27.20% RSI (14)36.29 Volatility5.98% 5.06%
OptionableYes Debt/Eq0.57 EPS Q/Q46.20% Profit Margin-26.80% Rel Volume3.15 Prev Close15.56
ShortableYes LT Debt/Eq0.57 EarningsFeb 14 AMC Payout- Avg Volume822.96K Price14.30
Recom2.90 SMA20-9.82% SMA50-11.62% SMA200-35.18% Volume2,589,168 Change-8.10%
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Apr-22-15Resumed Piper Jaffray Neutral
Feb-12-15Initiated MLV & Co Buy $58
Feb-15-19 10:29AM  Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates Zacks -8.10%
10:02AM  Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-14-19 05:25PM  Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates Zacks
04:28PM  Acorda: 4Q Earnings Snapshot Associated Press
04:00PM  Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018 Business Wire
07:50AM  The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga
Feb-06-19 08:40AM  Array BioPharma (ARRY) Soars: Stock Adds 11% in Session Zacks
Feb-04-19 07:00AM  Acorda Appoints Peter S. Carbone Senior Vice President, Quality Business Wire
Feb-01-19 07:55AM  Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific New Research Emphasizes Economic Growth GlobeNewswire
07:00AM  Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019 Business Wire
Jan-31-19 09:30AM  Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year? Zacks
Jan-29-19 02:05PM  Have Insiders Been Selling Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares? Simply Wall St.
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
Jan-22-19 09:31AM  Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids Zacks
08:39AM  Aerpio (ARPO) Jumps: Stock Rises 7.8% Zacks
Jan-17-19 06:30PM  Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA (levodopa inhalation powder) Business Wire
Jan-15-19 08:58AM  Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7% Zacks
Jan-14-19 09:46AM  ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks
08:42AM  Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher Zacks
Jan-10-19 10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks
Jan-07-19 08:46AM  Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9% Zacks
08:00AM  Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference Business Wire
Dec-26-18 09:47AM  Company News For Dec 26, 2018 Zacks +13.87%
09:45AM  Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James Benzinga
09:34AM  Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal Zacks
07:30AM  Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 01:30PM  Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today Motley Fool +6.41%
01:11PM  Biotech Stock Flies After FDA Approves Parkinson's Treatment Investor's Business Daily
09:41AM  Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy Bloomberg
08:59AM  Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija Zacks
07:20AM  Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK MarketWatch
07:00AM  ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA (levodopa inhalation powder) Business Wire
Dec-21-18 09:53PM  Acorda Therapeutics Announces FDA Approval of INBRIJA (levodopa inhalation powder) Business Wire -7.11%
Dec-19-18 07:00AM  Acorda to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire -7.99%
Dec-17-18 06:45AM  Acorda Therapeutics PDUFA Date, Pipeline Review and Third Quarter Highlights ACCESSWIRE
Dec-14-18 12:45PM  Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy? Insider Monkey
Dec-11-18 05:49PM  Here's Why Acorda Therapeutics Shares Sunk 15% Today Motley Fool -15.08%
Dec-05-18 07:00AM  Acorda Launches Art Initiative to Foster Better Conversations About Parkinsons Symptoms Business Wire
Nov-27-18 02:37PM  Should You Worry About Acorda Therapeutics Incs (NASDAQ:ACOR) CEO Pay? Simply Wall St.
Nov-15-18 09:34AM  Acorda Down More Than 30% in the Past 3 Months: Here's Why Zacks
Nov-13-18 09:41AM  Edited Transcript of ACOR earnings conference call or presentation 31-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 08:10AM  Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
07:00AM  Acorda to Present at Stifel 2018 Healthcare Conference Business Wire
Nov-01-18 12:50PM  Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up Zacks +5.60%
Oct-31-18 11:53AM  Acorda Therapeutics Inc (ACOR) Q3 2018 Earnings Conference Call Transcript Motley Fool +9.32%
07:35AM  Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates Zacks
06:30AM  Acorda: 3Q Earnings Snapshot Associated Press
06:00AM  Acorda Provides Financial and Pipeline Update for Third Quarter 2018 Business Wire
Oct-27-18 10:23AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs Benzinga
Oct-23-18 10:57AM  Centene's (CNC) Earnings and Revenues Top Estimates in Q3 Zacks
Oct-17-18 07:40AM  Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries Discovering Underlying Factors of Influence GlobeNewswire
07:00AM  Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled for October 31, 2018 Business Wire
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-08-18 07:30AM  The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga
Oct-02-18 07:00AM  Acorda to Present Data for INBRIJA (levodopa inhalation powder) at International Congress of Parkinsons Disease and Movement Disorders Business Wire -5.01%
Sep-14-18 11:00AM  Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija Zacks
Sep-13-18 04:28PM  Qualcomm and Tailored Brands rise; Kroger stumbles Associated Press
11:07AM  Here's Why Acorda Therapeutics Is Falling by Double Digits Today Motley Fool
07:43AM  Acorda shares slide 19% premarket after FDA delays review of Parkinson's treatment MarketWatch
07:00AM  Acorda Announces FDA Extends INBRIJA NDA Review Period Business Wire
Sep-11-18 09:16AM  Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down Zacks -7.45%
08:44AM  Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock? Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Acorda Therapeutics and Avid Bioservices ACCESSWIRE
Sep-10-18 04:41PM  Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today Motley Fool -24.50%
04:38PM  What's Behind Acorda Therapeutics Crashing 24.5% Today Motley Fool
12:01PM  Acorda's stock plunges after disappointing ruling regarding patents for MS treatment MarketWatch
11:47AM  U.S. Court of Appeals for the Federal Circuit Upholds District Courts Decision to Invalidate AMPYRA® (dalfampridine) Patents Business Wire
Aug-14-18 07:50AM  Market Trends Toward New Normal in Acorda Therapeutics, Red Robin Gourmet Burgers, Plug Power, Group 1 Automotive, Shutterfly, and National Fuel Gas Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:00AM  Acorda Announces Management Transitions Business Wire
Aug-13-18 11:34PM  Edited Transcript of ACOR earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-03-18 12:02PM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
08:48AM  Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock? Zacks
Aug-02-18 07:30AM  Acorda Therapeutics (ACOR) Q2 Earnings and Revenues Beat Estimates Zacks +5.05%
06:30AM  Acorda Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:21AM  Acorda: 2Q Earnings Snapshot Associated Press
06:00AM  Acorda Provides Financial and Pipeline Update for Second Quarter 2018 Business Wire
Jul-27-18 11:53AM  Collaborations Help Alkermes Flip to Profitability Motley Fool
Jul-25-18 02:11PM  Acorda Therapeutics denied motion in patent case, stock slides 17% MarketWatch -14.46%
Jul-24-18 07:58AM  What's in Store for Cardinal Health (CAH) in Q4 Earnings? Zacks
Jul-23-18 11:06AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jul-20-18 02:25PM  Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings? Zacks
Jul-19-18 03:08PM  5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
07:00AM  Acorda Second Quarter Update: Webcast/Conference Call Scheduled for August 2, 2018 Business Wire
Jun-30-18 05:32PM  The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus Benzinga
Jun-25-18 08:55AM  Implied Volatility Surging for Acorda (ACOR) Stock Options Zacks
Jun-18-18 07:00AM  Acorda to Present Data for INBRIJA (levodopa inhalation powder) at 2nd Pan American Parkinsons Disease and Movement Disorders Congress Business Wire
Jun-11-18 08:44AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher Zacks +7.24%
08:10AM  Todays Research Reports on Stocks to Watch: Acorda Therapeutics and TrovaGene ACCESSWIRE
Jun-08-18 01:02PM  Here's Why Acorda Therapeutics Rose as Much as 30.3% Today Motley Fool +8.96%
Jun-01-18 10:38AM  Acorda (ACOR) Up 13.4% Since Earnings Report: Can It Continue? Zacks
07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
07:05AM  Blog Exposure - Gilead Announces Approval of Epclusa in China ACCESSWIRE
May-30-18 08:14AM  Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA Benzinga
May-29-18 07:00AM  Acorda Announces EMA Validation of the MAA Submission for INBRIJA (levodopa inhalation powder) Business Wire
May-15-18 07:55AM  Detailed Research: Economic Perspectives on First American, Greenhill & Co., Acorda Therapeutics, Deckers Outdoor, World Fuel Services, and Spirit Aerosystems What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-03-18 11:39AM  Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y Zacks
11:30AM  Edited Transcript of ACOR earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-02-18 06:14AM  Acorda: 1Q Earnings Snapshot Associated Press
06:00AM  Acorda Provides Financial and Pipeline Update for First Quarter 2018 Business Wire
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 30Sale16.017,000112,0394,750,219Feb 01 04:28 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 25Sale16.002,40138,4164,757,219Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 24Sale16.038,600137,8514,759,620Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 23Sale16.0145,898734,9424,768,220Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 22Sale16.0251,945831,9724,814,118Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 18Sale16.2439,358639,3274,866,063Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 17Sale16.86100,0001,685,5504,905,421Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 16Sale16.9491,6501,552,4145,005,421Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 15Sale16.601,70028,2235,097,071Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 11Sale17.4040,392702,7885,098,771Jan 15 04:32 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 10Sale17.2987,4911,512,7285,139,163Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 09Sale17.0575,0001,278,7055,226,654Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 08Sale16.2459,174960,9275,301,654Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 07Sale16.5675,0001,241,7385,360,828Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 04Sale16.6131,591524,7145,435,828Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 03Sale15.7423,616371,6455,467,419Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 28Sale14.9952,891792,7515,491,035Jan 02 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 27Sale14.6650,000732,7605,543,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 26Sale14.6650,000732,8205,593,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 21Sale13.2440,506536,0975,643,926Dec 26 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 20Sale14.0340,000561,3685,684,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 19Sale15.935,00079,6645,724,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 18Sale16.9480,0001,354,9415,729,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 17Sale16.4941,853690,1025,809,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 14Sale16.1528,796464,9785,851,285Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 13Sale16.2733,061537,7605,880,081Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 12Sale16.30100,0001,629,7905,913,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 11Sale16.30200,0003,259,5006,013,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 10Sale19.0735,000667,5316,213,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 07Sale18.7725,210473,0716,248,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 06Sale18.4340,711750,3406,273,352Dec 07 04:45 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 04Sale20.603,09063,6596,314,063Dec 07 04:45 PM
Wasman JanePresident, Intl and GCDec 03Sale20.523,06762,947105,287Dec 06 08:42 AM
Sabella Lauren MChief Commercial OfficerDec 03Sale20.565,191106,7371,568Dec 06 08:31 AM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 03Sale20.552,49351,2323,653Dec 06 08:22 AM
Hindman Andrew A.Chief Business OfficerDec 03Sale20.5675315,4785,171Dec 06 08:05 AM
COHEN RONPresident and CEODec 03Sale20.603,62074,554487,554Dec 06 08:00 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 03Sale20.70100,0002,069,5006,317,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 30Sale20.4875,0001,536,0156,417,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 29Sale20.2050,0001,009,8606,492,153Dec 03 05:03 PM
Randall LorinDirectorNov 26Sale19.981,90438,0340Nov 28 08:02 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 11Sale17.0949,760850,5486,542,153Oct 12 04:16 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 10Sale16.9193,8161,586,7576,591,913Oct 12 04:16 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 09Sale16.4956,290928,0766,685,729Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 08Sale17.8760,0421,073,1976,742,019Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 05Sale17.5137,526657,0546,802,061Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 04Sale18.8937,526708,7506,839,587Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 03Sale19.4856,2891,096,2796,877,113Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 02Sale18.8932,649616,7046,933,402Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerSep 06Sale27.8213,829384,6837,106,955Sep 06 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerSep 04Sale29.002005,8007,120,784Sep 06 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerAug 28Sale29.4120,256595,6587,120,984Sep 06 04:14 PM
BLANK BURKHARDChief Medical OfficerAug 01Option Exercise16.506,250103,12534,400Aug 03 07:46 AM
BLANK BURKHARDChief Medical OfficerAug 01Sale24.696,250154,32228,150Aug 03 07:46 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 25Sale28.8911,551333,7417,141,240Jul 25 05:20 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 24Sale28.6950,0001,434,5507,152,791Jul 25 05:20 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 23Sale28.3225,000708,0257,202,791Jul 25 05:20 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 20Sale29.0521,580626,8957,227,791Jul 20 04:43 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 19Sale29.1565,7001,914,8597,249,371Jul 20 04:43 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 18Sale28.9721,460621,7337,315,071Jul 20 04:43 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 17Sale30.058,199246,3547,336,531Jul 17 05:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 16Sale30.0425,000750,9787,344,730Jul 17 05:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 13Sale30.001003,0007,369,730Jul 17 05:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 10Sale30.278,226248,9807,369,830Jul 10 05:13 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 09Sale30.2732,128972,5507,378,056Jul 10 05:13 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 06Sale30.70160,0004,911,2647,410,184Jul 10 05:13 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 05Sale30.1027,093815,3807,570,184Jul 05 05:23 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 03Sale30.013,400102,0507,597,277Jul 05 05:23 PM
BLANK BURKHARDChief Medical OfficerJul 02Sale29.615,000148,05028,150Jul 03 05:33 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJul 02Sale30.0635,8891,078,8707,600,677Jul 05 05:23 PM
Sabella Lauren MChief Commercial OfficerJun 28Sale27.845,859163,1405,306Jul 02 07:52 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 21Sale30.5360,2951,840,6507,636,566Jun 25 06:39 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 20Sale30.3758,7001,782,5967,696,861Jun 20 08:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 19Sale30.6391,0702,789,0927,755,561Jun 20 08:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 18Sale30.77243,4147,490,9207,846,631Jun 20 08:09 PM
SMITH IAN FDirectorJun 15Option Exercise18.4625,000461,50025,000Jun 19 04:19 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 15Sale31.5029,114917,1178,090,045Jun 15 08:18 PM
SMITH IAN FDirectorJun 15Sale31.4225,000785,5680Jun 19 04:19 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 14Sale31.5487,7962,769,2798,119,159Jun 15 08:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 13Sale31.71100,0003,171,2608,206,955Jun 15 08:18 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOJun 12Sale31.743,431108,9044,693Jun 13 08:00 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 12Sale31.5853,6001,692,6568,306,955Jun 12 08:46 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOJun 08Option Exercise20.595,120105,42113,244Jun 11 07:44 AM
Sabella Lauren MChief Commercial OfficerJun 08Option Exercise16.5024,375402,18835,540Jun 12 07:40 AM
Sabella Lauren MChief Commercial OfficerJun 08Sale35.0024,375853,12511,165Jun 12 07:40 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJun 08Sale31.13114,1733,553,8068,360,555Jun 12 08:46 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOJun 08Sale28.875,120147,8078,124Jun 11 07:44 AM
LAWRENCE DAVIDChief, Bus. Ops & PAOJun 07Option Exercise20.5919,880409,32928,004Jun 11 07:44 AM
LAWRENCE DAVIDChief, Bus. Ops & PAOJun 07Sale28.0219,880556,9768,124Jun 11 07:44 AM
Hindman Andrew A.Chief Business OfficerMay 25Sale24.2642,6151,034,0064,503May 30 07:51 AM
Greene Barry EDirectorMay 21Option Exercise20.1610,000201,60010,000May 23 07:35 AM
BLANK BURKHARDChief Medical OfficerMay 18Option Exercise16.5025,000412,50058,150May 22 04:33 PM
Sabella Lauren MChief Commercial OfficerMay 18Sale23.677,288172,47111,165May 22 04:35 PM
BLANK BURKHARDChief Medical OfficerMay 18Sale23.6625,000591,58833,150May 22 04:33 PM
RAUSCHER STEVEN MDirectorMay 15Option Exercise20.1610,000201,60010,000May 17 07:43 AM
RAUSCHER STEVEN MDirectorMay 15Sale24.5910,000245,8530May 17 07:43 AM
SMITH IAN FDirectorMay 02Option Exercise20.1610,000201,60010,000May 04 05:50 PM
SMITH IAN FDirectorMay 02Sale23.7210,000237,1750May 04 05:50 PM
Randall LorinDirectorMar 06Option Exercise20.1610,000201,60010,000Mar 08 08:02 AM
Wasman JanePresident, Intl and GCMar 05Option Exercise19.812,98059,034111,553Mar 07 07:54 AM